Lung Cancer Screening Market Trends 2032: Biomarker‑Driven Liquid Biopsy Testing

The lung cancer screening market is experiencing significant growth as healthcare systems shift toward early detection strategies. Screening methods—such as low-dose CT (LDCT), chest X-rays, and liquid biopsies—are increasingly used to identify lung cancer at treatable stages. Key drivers include rising lung cancer incidence, especially among smokers, technological innovations (including AI-enhanced imaging and minimally invasive diagnostics), and enhanced public awareness. While the market faces challenges like high equipment costs and limited access in some regions, improved reimbursement policies, awareness programs, and emerging technologies are expanding reach. As early detection becomes standard in high-risk populations, the lung cancer screening market is poised for sustained global growth.

According to Fortune Business Insights, the global lung cancer screening market was valued at USD 3.28 billion in 2023. The market is projected to grow from USD 3.55 billion in 2024 to USD 7.10 billion by 2032, exhibiting a CAGR of 9.1% during the forecast period. In 2023, North America dominated the lung cancer screening market with a market share of 54.27%.

Leading Companies Shaping the Market Landscape

• Koninklijke Philips N.V. (Amsterdam, Netherlands)

• Siemens Healthineers AG (Munich, Germany)

• Canon Medical Systems Corporation (Tochigi, Japan)

• GE Healthcare (Chicago, U.S.)

• FUJIFILM Holdings Corporation (Tokyo, Japan)

• Medtronic (Dublin, Ireland)

• Nuance Communications, Inc. (Burlington, U.S.)

• Eon (Denver, U.S.)

• PenRad Technologies, Inc. (Minnesota, U.S.)

• Volpara Solutions Limited (Wellington, New Zealand)

🚀 Key Industry Development: January 2024

In January 2024, Nova Scotia launched a new lung cancer screening program targeting high-risk individuals—a significant public health milestone that underscores the push for nationwide early detection strategies.

Market Drivers & Restraints

🔍 Key Growth Drivers

• Higher Disease Prevalence: Rising cases of lung cancer—especially due to smoking—are accelerating demand for screening solutions.

• Technological Innovation: Development of low-dose spiral CT scans, AI-assisted diagnostics, and liquid biopsies are increasing both screening accuracy and adoption.

• Government Initiatives & Awareness Campaigns: Programs like Nova Scotia's launch and Lung Cancer Awareness Month initiatives in the U.S. are boosting public uptake.

• FDA Reimbursement & Guidelines: Policies backing low-dose CT scans, shown to reduce mortality up to 20 %, are fueling their increased use.

⚠️ Key Restraints

• High Screening Cost: A typical low-dose CT scan costs around USD 300 in the U.S., limiting access in low- and middle-income areas.

• Limited Infrastructure: Shortages of CT equipment and qualified personnel—particularly radiologists—in developing regions hamper implementation.

Market Segmentation & Trends

By Cancer Type

Non-Small Cell Lung Cancer (NSCLC): This segment dominates the market, generating the highest revenue due to its higher prevalence (~84% of cases) and improved survival rates estimated at 24% over five years.

Small Cell Lung Cancer (SCLC): While smaller in share, it remains significant due to the overall rise in lung cancer incidence and greater screening needs.

By Diagnosis Type

Low-Dose Spiral CT (LDCT): Holds the largest share, driven by evidence from multiple trials (e.g., National Lung Screening Trial, NELSON) that LDCT reduces mortality by ~20 %.

Chest X-Ray: Still used, but expanding less rapidly due to LDCT's superior detection capabilities.

By End-User

Hospitals & Clinics: Leading the market due to extensive infrastructure and preference for comprehensive diagnostic settings.

Diagnostic Centers: Gaining traction as partnerships between healthcare providers and diagnostic chains expand screening outreach.

Regional Insights

North America

Dominating with 54.27% market share in 2023 (~USD 1.78 billion), primarily driven by U.S. screening programs, high smoking rates, and policy support.

Europe

Second largest, benefiting from established healthcare systems and data from trials like NELSON and UKLS that support national screening reimbursement.

Asia-Pacific

Fastest-growing region due to rising smoking prevalence, public health efforts, and investment in CT-scan infrastructure.

Latin America & MEA

Growing slowly—limited by low awareness and infrastructure—but poised for expansion as regional investment in healthcare strengthens.

Technological Trends Driving Market Evolution

• AI-Assisted Imaging: AI platforms are automating cancer detection, reducing radiologist workload, and enhancing diagnostic accuracy.

• Liquid Biopsies: Companies like Delfi Diagnostics and research centers like MIT are pioneering non-invasive screening options via nanoparticle sensors and blood-based assays.

• Smart CT Scanners: Low-dose spiral CT continues to lead due to improved imaging resolution and lower radiation exposure.

Competitive Landscape

The market is consolidated, led by key players with strong portfolios, distribution, and innovation, including:

• Koninklijke Philips N.V.: Known for tools like the Azurion Lung Edition platform .

• GE Healthcare, Siemens Healthineers, Canon Medical: Leading in advanced CT equipment.

• FUJIFILM, Volpara, PenRad, Eon, Nuance: Focused on imaging software, analytics, and AI-based detection.

Companies are also forging diagnostic-to-treatment pipelines. For instance, Genentech and Roche’s 2019 collaboration on biomarker screening explores genome-based early detection.

Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/industry-reports/lung-cancer-screening-market-101174 

Outlook & Future Market Scope

Looking ahead, the lung cancer screening market is poised for further transformation:

• Broader Screening Guidelines: Expanding criteria to include non-smokers and younger adults could significantly enlarge the target population.

• Enhanced Reimbursement Policies: Extended coverage for LDCT scans may boost adoption, especially in underindexed regions.

• Emerging Innovation: Liquid biopsy and inhalable nanoparticle sensors may redefine non-invasive screening approaches .

• AI Integration: Integration of AI across imaging systems can scale access and improve early detection accuracy.

• Public Health Campaigns: Global awareness efforts and public-private partnerships will be instrumental in improving screening uptake.

Conclusion

The global lung cancer screening market is entering a period of sustained growth, fueled by advanced diagnostic technologies, rising disease burden, and strengthened public health frameworks. With projections reaching USD 7.10 billion by 2032, stakeholders—including manufacturers, healthcare providers, and public health agencies—must collaborate to overcome cost and capacity barriers and fully harness early detection’s life-saving potential.

About Us:

Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.

Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free),

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com